Psychedelics are fully legal in very few places, but a growing number of countries allow them in specific contexts: supervised therapy, religious ceremonies, or through legal loopholes that leave certain substances unregulated. The global picture is a patchwork of medical programs, decriminalization policies, and grey areas that vary by substance and country.
The Netherlands: Psilocybin Truffles
The Netherlands is one of the few countries where you can legally buy and consume a psilocybin product over the counter. Psilocybin truffles (technically called sclerotia, the underground part of the mushroom organism) are sold openly in “smart shops” across the country. The distinction matters: dried psilocybin mushrooms were banned in 2008 after several high-profile incidents, but truffles were not included in that ban. They contain the same active compound and produce the same effects. Other psychedelics, including LSD and MDMA, remain illegal. Ibogaine, a psychedelic used in addiction treatment, is also unregulated in the Netherlands, making the country a destination for ibogaine therapy clinics.
Jamaica: Legal by Omission
Psilocybin mushrooms were never listed under Jamaica’s Dangerous Drugs Act, which means they remain completely unregulated. This isn’t decriminalization or a medical exception. Mushrooms simply have no legal prohibition on the island. That gap has given rise to a growing psilocybin retreat industry, with centers offering guided experiences to international visitors. There is no licensing framework or dosing standard, so the quality and safety of these retreats varies widely.
Brazil: Ayahuasca as Religious Practice
Brazil is the clearest example of a country protecting psychedelic use through religious freedom. Ayahuasca, a brew containing the powerful psychedelic DMT, has been legal for use in religious rituals since at least 1991, when the government issued its first formal guidelines for ayahuasca-using religious groups. A 2010 resolution reaffirmed those protections, permitting ayahuasca use within the context of religious ceremonies. The legal framework grew partly from court battles by the União do Vegetal (UDV), one of Brazil’s largest ayahuasca churches, which won a favorable ruling as early as 1971 allowing it to explicitly reference ayahuasca use in its bylaws. The protections apply specifically to religious contexts, not recreational or commercial use. An effort to register ayahuasca as “intangible cultural heritage,” which would have unlocked public funding, has not succeeded, but the 2010 resolution remains unchallenged.
Peru and Colombia also permit traditional ayahuasca use, and both countries host large ayahuasca tourism industries. In Peru, ayahuasca is considered part of the country’s cultural heritage, and indigenous shamanic ceremonies operate openly.
Australia: Prescription Psilocybin and MDMA
Australia became the first country to formally recognize psilocybin and MDMA as prescription medicines for specific psychiatric conditions. Since July 1, 2023, authorized psychiatrists can prescribe psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder. The prescribing psychiatrist must be approved under the Therapeutic Goods Administration’s Authorised Prescriber scheme, which limits access to a small number of specialists. This is not a system where a general practitioner can write a prescription. Patients must have a diagnosed condition that has not responded to conventional treatments, and the therapy is administered under clinical supervision.
Oregon and Colorado: Supervised Use in the U.S.
No U.S. state has legalized psychedelics for personal use in the way cannabis has been legalized. What Oregon and Colorado have done is create regulated frameworks for supervised psilocybin experiences.
Oregon’s program, which began accepting clients in 2023, requires that psilocybin be purchased, possessed, and consumed only at a licensed psilocybin service center and only under the supervision of a trained facilitator. You cannot take psilocybin home. Service centers must be operated by someone 21 or older with a state license, cannot be located in areas zoned exclusively for residential use, and must be at least 1,000 feet from elementary and secondary schools. Mobile facilities are not allowed. Cities and counties can opt out of the program entirely, and many have.
Colorado passed a similar measure in 2022 and is building out its regulated access program, which will also center on supervised sessions at licensed facilities rather than retail sales. Colorado’s law also includes provisions for additional plant-based psychedelics beyond psilocybin, including DMT, ibogaine, and mescaline (excluding peyote).
Several U.S. cities, including Denver, Oakland, Santa Cruz, Seattle, and Washington D.C., have separately deprioritized enforcement of laws against psilocybin and other natural psychedelics. This means police are directed to treat these substances as their lowest enforcement priority, but possession technically remains a federal crime throughout the United States.
Canada: Case-by-Case Medical Access
Canada allows access to psilocybin and MDMA through its Special Access Program (SAP), which has permitted requests for restricted drugs since January 2022. The process is individual and tightly controlled. A licensed health care practitioner must submit a patient-specific request form that includes the drug name, the quantity needed, the manufacturer, and a detailed explanation of why conventional treatments have failed or are unsuitable. The request must also include evidence supporting the drug’s safety and effectiveness for that patient’s specific condition.
If Health Canada authorizes the request, it issues a letter permitting the manufacturer to sell the specified quantity to the practitioner. For ongoing treatment, the practitioner must report back on the patient’s response relative to initial treatment goals before requesting more. Every authorization is case-by-case, meaning there is no blanket approval for any practitioner or condition.
Switzerland: Exceptional Licenses for Therapy
Switzerland has allowed limited psychedelic-assisted therapy through an exceptional licensing system administered by the Federal Office of Public Health. Swiss doctors can apply for exceptional licenses that permit the handling of otherwise banned narcotics for specific therapeutic purposes. LSD and MDMA have both been used under this framework, primarily for patients with serious psychiatric conditions who have not responded to standard treatment. The number of licenses granted has grown in recent years, but the system remains restrictive and physician-initiated.
Portugal: Decriminalized, Not Legal
Portugal is often cited in conversations about drug legality, but it’s important to understand what decriminalization actually means there. Since 2001, possessing any drug for personal use is an administrative offense rather than a criminal one. The threshold for “personal use” is defined as a 10-day supply for an average individual. For ecstasy (which contains MDMA), that limit is 1 gram. For amphetamines, it’s also 1 gram. Cannabis is set at 25 grams. Specific thresholds for psilocybin and LSD are less clearly defined in the published schedules, but the same 10-day principle applies.
If you’re found with quantities below the threshold, you receive a citation to appear before a local Commission for the Dissuasion of Drug Addiction, which can recommend treatment, impose a fine, or take no action. Possession above the threshold can lead to criminal trafficking charges. The substances themselves remain illegal to sell, produce, or distribute. Portugal’s model reduces the personal consequences of drug use but does not create any legal supply or supervised access.
Costa Rica: A Common Misconception
Costa Rica is frequently mentioned as a destination for ibogaine treatment or ayahuasca retreats, but the legal picture is more complicated than many retreat operators suggest. The Costa Rican Ministry of Health has issued direct warnings against the advertising, use, and consumption of ayahuasca and ibogaine for therapeutic purposes, stating that these substances lack the required sanitary registration. Any medicine or therapeutic product in the country requires prior registration and evaluation, which neither substance has undergone. Retreats and ceremonies continue to operate, particularly in areas popular with tourists and expats, but they do so without government authorization. The Ministry has explicitly advised the public to avoid consuming these substances or attending ceremonies that use them.
Where Things Stand Globally
The only places where you can walk in and legally consume a psychedelic without a prescription or clinical authorization are the Netherlands (psilocybin truffles) and Jamaica (psilocybin mushrooms). Brazil protects ayahuasca use in religious settings. Australia, Canada, and Switzerland have medical access pathways that require psychiatric oversight and, in most cases, evidence that other treatments have failed. Oregon and Colorado offer supervised psilocybin sessions at licensed facilities. Portugal and a handful of U.S. cities have reduced penalties for possession but haven’t legalized supply. Everywhere else, psychedelics remain controlled substances under both domestic law and the 1971 United Nations Convention on Psychotropic Substances, which most countries have ratified.